OncoMatch/Clinical Trials/NCT03826992
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Is NCT03826992 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Vyxeos and Venetoclax for leukemia.
Treatment: Vyxeos · Venetoclax — This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not responded to treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Biomarker criteria
Required: KMT2A (MLL) rearranged
KMT2A-rearranged ALL
Excluded: KMT2A (MLL) rearrangement
MPAL with KMT2A-rearrangement are NOT eligible
Excluded: BCR t(9;22)
Philadelphia chromosome t(9;22) positive leukemia (Ph+ ALL, AML, MPAL, or AUL)
Demographics
Prior therapy
Must have received: hematopoietic stem cell transplant
Fully recovered from acute toxicities of Hematopoietic Stem Cell Transplant (HSCT)
Must have received: anthracycline
Fully recovered from acute toxicities of ... Anthracycline Exposure
Cannot have received: growth factors
Receipt of growth factors within 7 days prior to enrollment
Cannot have received: radiation therapy
Exception: greater than 13.6 Gray (Gy) prior radiation to the mediastinum
Received greater than 13.6 Gray (Gy) prior radiation to the mediastinum
Lab requirements
Kidney function
adequate renal function
Liver function
adequate liver function
Cardiac function
adequate cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cincinnati Children's Hospital Medical Center · Cincinnati, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03826992 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior growth factors, radiation therapy disqualifies patients from enrollment.
Does this trial require KMT2A?
Yes, KMT2A rearranged is a required biomarker for enrollment.
Are patients with KMT2A alterations eligible?
No. KMT2A rearrangement is an exclusion criterion.
Are patients with BCR alterations eligible?
No. BCR t(9;22) is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 39 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify